

## Annex B. NM Diagnostic activity by country – Data sources and comparability

Estimates of the number of procedures in Chapter 2 are collated from various sources described in the table below. Some estimates include all NM diagnostic procedures for which the use of Tc-99m is possible (single- and multi-phase planar scintigraphies, SPECT and SPECT/CT), irrespective of the radioisotope actually used, while some estimates only include procedures using Tc-99m. All estimates exclude NM diagnostic procedures for which the use of Tc-99m can be ruled out (e.g. PET).


Estimates in of the proportion of procedures by organ system in Chapter 2 are based on the same data sources and described below. For Australia, only Medicare statistics are used to estimate the proportion of scans by organ systems; no data are available on activity in public hospitals and other providers that are not subsidised by Medicare.

**Table A B.1. Data on the number of NM diagnostic scans by country**

### Data sources and comparability

Country	Year	Source	Notes
Australia	2017	Medicare Statistics 2018; ANSTO press releases	Includes all NM diagnostic procedures subsidised by Medicare, based on MBS items in "Group:14 Nuclear Medicine Imaging." MBS billing codes are not always specific to the isotope used; excludes MBS items for which use of Tc-99m can be ruled out. Medicare assumed to represent 70% of total (excluding scans in public hospitals), based on ANSTO estimates of Australian Tc-99m market size.
Austria	2007-10	European Commission RP Report 180	Tc-99m only
Belgium	2015-17	OECD HD survey, estimated based on several national surveys	Excludes services where radioisotope can be identified as non-Tc-99m.
Canada	2015-17	CADTH The Canadian Medical Imaging Inventory 2017; OECD HD survey	CADTH reports number of SPECT and SPECT-CT scans by province and for all of Canada; sum of SPECT and SPECT-CT assumed to represent 65% of total based on SPECT and SPECT-CT reported by CADTH and total number of NM scans in BC and Manitoba reported in OECD Health Division Survey. Tc-99m assumed to represent 85% of total.
Czech Republic	2007-10	OECD HD survey	Tc-99m only
Denmark	2007-10	EC RP180	Tc-99m only
Estonia	2007-10	EC RP180	Tc-99m only
Finland	2007-10	EC RP180	Tc-99m only
France	2017	L'Assurance Maladie	Includes all NM diagnostic scans per the national nomenclature of medical procedures CCAM in in- and out-patient settings of private and public providers, except PET. Tc-99m assumed to

Country	Year	Source	Notes
			represent 85% of total.
Germany	2015	Hellwig et al. 2017 based on national KBV and G-DRG statistics	All outpatient NM diagnostic procedures paid by SHI except PET, and inpatient scintigraphy, SPECT and SPECT/CT procedures coded to G-DRGs. Outpatient activity broken down by isotope; data on inpatient activity does not isolate Tc-99m. Outpatient SHI sector assumed to represent 90% of total SHI and private insurance activity.
Greece	2007-10	EC RP180	Tc-99m only
Hungary	2007-10	EC RP180	Tc-99m only
Ireland	2007-10	EC RP180	Tc-99m only
Italy	2007-10	EC RP180	Tc-99m only
Japan	2017	Subcommittee on Survey of Nuclear Medicine Practice in Japan, Report of the 8th Nationwide Survey in 2017	Tc-99m only, representing 61% of all NM diagnostic scans excl. PET.
Latvia	2017	OECD HD survey	Tc-99m only
Lithuania	not specified	OECD HD survey	Tc-99m only; midpoint of range provided in response to OECD Health Division survey (5 800 to 6 400 Tc-99m scans / per year).
Luxembourg	2016	OECD HD survey	All NM diagnostic procedures excl. PET. Tc-99m assumed to represent 85% of total.
Netherlands	2015	OECD HD survey	Tc-99m only; all NM diagnostic procedures excl. PET based on results of a national provider survey provided by respondents to the OECD HD survey. Tc-99m assumed to represent 85% of total.
Poland	2007-10	EC RP180	Tc-99m only
Portugal	2007-10	EC RP180	Tc-99m only
Slovak Republic	2007-10	EC RP180	Tc-99m only
Slovenia	not specified	OECD HD survey	Tc-99m only
Spain	2007-10	EC RP180	Tc-99m only
Sweden	2017	OECD HD survey	Tc-99m only
United Kingdom (England)	FY 2016/17	NHS England Diagnostic Imaging Dataset	All Tc-99m scans in NHS hospitals (in- and outpatient). England assumed to represent 85% of UK total based on population.
United States	2014	IMV 2015 Nuclear Medicine Benchmark Report	Based on IMV Medical Information Division 2015 survey of U.S. hospitals and non-hospitals that perform NM procedures using fixed SPECT/CT, SPECT, and planar only cameras. A total of 407 respondents, 283 from hospitals and 124 from non-hospital locations, extrapolated to a provider population of 7 091 sites (4 040 hospitals and 3 051 non-hospital locations). Tc-99m assumed to represent 85% of total.



**From:**  
**The Supply of Medical Isotopes**  
An Economic Diagnosis and Possible Solutions

**Access the complete publication at:**

<https://doi.org/10.1787/9b326195-en>

**Please cite this chapter as:**

OECD/Nuclear Energy Agency (2019), "NM Diagnostic activity by country – Data sources and comparability", in *The Supply of Medical Isotopes: An Economic Diagnosis and Possible Solutions*, OECD Publishing, Paris.

DOI: <https://doi.org/10.1787/ac33aeaf-en>

This work is published under the responsibility of the Secretary-General of the OECD. The opinions expressed and arguments employed herein do not necessarily reflect the official views of OECD member countries.

This document and any map included herein are without prejudice to the status of or sovereignty over any territory, to the delimitation of international frontiers and boundaries and to the name of any territory, city or area.

You can copy, download or print OECD content for your own use, and you can include excerpts from OECD publications, databases and multimedia products in your own documents, presentations, blogs, websites and teaching materials, provided that suitable acknowledgment of OECD as source and copyright owner is given. All requests for public or commercial use and translation rights should be submitted to [rights@oecd.org](mailto:rights@oecd.org). Requests for permission to photocopy portions of this material for public or commercial use shall be addressed directly to the Copyright Clearance Center (CCC) at [info@copyright.com](mailto:info@copyright.com) or the Centre français d'exploitation du droit de copie (CFC) at [contact@cfcopies.com](mailto:contact@cfcopies.com).